A year for change

Article

2009 has started with a bang...

2009 has started with a bang. Less than two weeks into the New Year, a shock announcement came from global healthcare and medical device firm Abbott, as it publicized its acquisition of AMO. For Abbott, the acquisition will see the addition of a brand new business division to its extensive medical device portfolio, allowing it to gain a brand new customer base and to further diversify risk; undeniably a positive move, particularly in these uncertain economic conditions. The purchase will also catapult Abbott into a leading position within the global ophthalmic market, which is previously unchartered territory for the company. For AMO, Abbott offers strong financial support as well as a new perspective for growth and expansion strategies. AMO can also capitalize on the healthcare firm’s strong reputation and global presence in international markets. So could this $2.8 billion deal spell the first in a long line of acquisitions for 2009? I think so!

Change has also been the theme for Ophthalmology Times Europe as we kick off 2009. Okay, so maybe the scale of our changes cannot quite match those of the AMO acquisition but you may have noticed that the look, size and style of this issue of your magazine have changed, we hope, to better suit your needs. Please do feel free to contact us if you would like to make any suggestions or comments.

I would now like to take this opportunity to wish you all a very happy New Year. May 2009 bring you good health, success, and continued enjoyment from your monthly edition of Ophthalmology Times Europe!

Fedra Pavloufpavlou@advanstar.com

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.